Article
05 Mar 2026
FDA Advances A "Plausible Mechanism" Framework For Rare Disease Drug Development And Signals A Shift To A Single Trial With Confirmatory Evidence Default For All Drugs
RANKINGS
This author falls within the Top 20% for their listed topics and industry categories. Based on Mondaq users readership, this author is ranked as VERY POPULAR in United States
AUTHORS CONTENT
Article
26 Jan 2026
FDA "Cuts Red Tape" On Clinical Decision Support Software And Wearable Products For General Wellness
Article
02 Jan 2026
The BIOSECURE Act Becomes Law In The United States
Article
20 Nov 2025
FDA's New "Plausible Mechanism Pathway" And Other Initiatives To Expedite Approval Of Drugs For Ultra-Rare Conditions
Article
06 Nov 2025
FDA Proposes To Eliminate Comparative Clinical Efficiency Studies For Biosimilars
Article
12 Sep 2025
DTC Reforms And MAHA Proclamations: The MAHA Agenda And Its Focus On Prescription Drugs Continues To Take Shape
Article
22 Aug 2025
Congress Revisits The BIOSECURE Act: Risks For Biotechnology Collaborations With Chinese Entities
Article
08 Aug 2025
Implications Of FDA's "Radical Transparency" Plan For Complete Response Letters
Article
29 Jul 2025
FDA Begins To Accept Nominations For The Commissioner's National Priority Voucher Pilot Program
Article
23 Jun 2025
FDA Announces Commissioner's National Priority Vouchers To Facilitate Expedited Access To Certain Drugs
Article
02 Jun 2025
AI, Medical Products & FDA, Part 1: AI Overview In Life Sciences (Podcast)
Article
14 May 2025
President Trump Issues Executive Order On Regulatory Relief To Promote Domestic Production Of Critical Medicines
Article
22 Apr 2025
Trump Administration Issues Executive Order To Lower Prescription Drug Costs
Article
20 Feb 2025
A First Look At The MAHA Era: Initial Thoughts For Industry Based On The MAHA Commission EO
Article
18 Feb 2025
The DOGE Workforce Optimization EO: Implications For FDA
Article
30 Jan 2025
FDA Finalizes Rule On ACNU Drugs, Signaling Opening For Next-Gen OTC Drugs
Article
27 Dec 2024
Recent SEC Case Against Biotech Company Highlights The Intersection Between FDA Findings And SEC Enforcement
Article
17 Dec 2024
FDA Issues New Draft Guidance For Expedited Program For Serious Conditions — Accelerated Approval Of Drugs And Biologics
Article
13 Nov 2024
The Convergence Of Life Sciences And Artificial Intelligence: Seizing Opportunities While Managing Risk
Article
15 Jul 2024
FDA Issues Revised Draft Guidance On Addressing Misinformation About Medical Devices And Prescription Drugs
